About Us

Minaris Regenerative Medicine is a leading global contract development and manufacturing organization (CDMO) dedicated to the production of cell and gene therapy products. For more than 20 years, we have been offering clinical and commercial manufacturing services, development solutions, and technologies while providing outstanding quality and reliability.

Our Vision: Creating Future Cell Therapy Miracles Together

Over 20 Years' Worth of Experience

Our state-of-the-art facilities located within the United States (New Jersey and California), Europe (Germany), and Asia (Japan) allow us to supply patients worldwide with life-changing therapies.

As a pioneer within this industry, we are proud to have built strong relationships with a number of international clients, ranging from big pharma to biotech to academia.

Our client-focused approach is designed to deliver world-class service to your specific needs and unique challenges. Our goal is to be viewed as your partner and an extension of your in-house team by delivering the expertise, strategy, teamwork, efficiency, and accessibility you demand. Doing so allows these life-changing therapeutics to be available to patients worldwide at an accelerated rate.

Our Mission: We commit our experience to our clients, by providing global manufacturing services, development solutions, and technologies for cell and gene therapies to improve society’s well-being.

Committing Our Experience to Clients and Patients

Since we began to support a paradigm shift in medicine more than 20 years ago, we have created a vision of creating cell therapy miracles with our clients to serve patients globally. Watch our video to learn more.

Minaris is derived from the Japanese word "mirai", meaning future, and the English word "miracle." Our new name stands for our commitment to constantly push the boundaries of medicine and provide future miracles to the patients we serve.

Our Global Reach

Minaris Regenerative Medicine is part of the Resonac Group with subsidiaries in three major world regions.

North America

Minaris Regenerative Medicine, LLC based in Allendale, NJ and Mountain View, CA, formerly named Hitachi Chemical Advanced Therapeutics Solutions (HCATS) and founded as Progenitor Cell Therapy (PCT) in 1999.

Europe

Minaris Regenerative Medicine GmbH based in Munich, Germany, formerly named apceth Biopharma GmbH and founded in 2007.

Asia

Minaris Regenerative Medicine Co., Ltd. based in Yokohama, formerly named Showa Denko Materials Co., Ltd., and founded as Hitachi Chemical Co., Ltd. in 2018.